Six chapters of technical depth
From camelid structural biology to preclinical immunoassay formats and research-grade binding reagents - grounded in peer-reviewed science throughout.
Written for the people doing the work
Research Scientists
Using nanobodies as research tools - GFP-Trap, intrabodies, chromobodies, cryo-EM chaperones, or proximity labelling systems.
Assay Developers
Building lateral flow, ELISA, HTRF, or multiplexed immunoassay platforms and evaluating nanobodies as a replacement for conventional antibody reagents.
Preclinical Assay Developers
Building and validating immunoassay platforms using nanobodies as research-grade capture and detection reagents, ahead of any downstream commercial or regulatory pathway.
Why nanobodies are changing preclinical research
Foundational nanobody patents are expiring - opening access to a binding reagent platform with properties conventional antibodies simply cannot match. This whitepaper gives you the technical grounding to understand what that means for your preclinical assays, your research tools, and your workflows.
- ✓Covers ELISA, HTRF, flow cytometry, lateral flow formats, and cryo-EM applications in a preclinical research context - written for scientists developing assays, not end-use diagnostics.
- ✓Explains what room-temperature stability, high-density conjugation, and resistance to harsh matrix conditions mean in practical assay terms.
- ✓Includes an honest account of the challenges - immunogenicity, lot standardisation, and GMP manufacturing - not just the advantages.
- ✓12 peer-reviewed references including Nature, PNAS, and Annual Review of Biochemistry, plus EMA regulatory data.
- ✓No cost, no subscription required. Instant PDF download on submission.
"Nanobodies are not a replacement for conventional antibodies - they are a complement, filling niches that larger molecules cannot access and enabling applications that were not previously possible."